GPCRs involved in metabolic diseases:pharmacotherapeutic development updates  

作　　者：Cheng Jin Hui Chen Li Xie Yuan Zhou Li-li Liu Jian Wu 

机构地区：[1]Department of Medical Microbiology&Parasitology,MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology,School of Basic Medical Sciences,Fudan University Shanghai Medical College,Shanghai,200032,China [2]College of Clinical Medicine,Fudan University Shanghai Medical College,Shanghai,200032,China [3]Department of Gastroenterology&Hepatology,Zhongshan Hospital of Fudan University,Shanghai,200032,China [4]Shanghai Institute of Liver Diseases,Fudan University Shanghai Medical College,Shanghai,200032,China

出　　处：《Acta Pharmacologica Sinica》2024年第7期1321-1336,共16页中国药理学报（英文版）

基　　金：supported partially by the National Natural Science Foundation of China (NSFC#82370625,82170624,81871997,81572356);the National Key R&D Program of China (#2016YFE0107400)to J.W.

摘　　要：G protein-coupled receptors(GPCRs)are expressed in a variety of cell types and tissues,and activation of GPCRs is involved in enormous metabolic pathways,including nutrient synthesis,transportation,storage or insulin sensitivity,etc.This review intends to summarize the regulation of metabolic homeostasis and mechanisms by a series of GPCRs,such as GPR91,GPR55,GPR119,GPR109a,GPR142,GPR40,GPR41,GPR43 and GPR120.With deep understanding of GPCR’s structure and signaling pathways,it is attempting to uncover the role of GPCRs in major metabolic diseases,including metabolic syndrome,diabetes,dyslipidemia and nonalcoholic steatohepatitis,for which the global prevalence has risen during last two decades.An extensive list of agonists and antagonists with their chemical structures in a nature of small molecular compounds for above-mentioned GPCRs is provided as pharmacologic candidates,and their preliminary data of preclinical studies are discussed.Moreover,their beneficial effects in correcting abnormalities of metabolic syndrome,diabetes and dyslipidemia are summarized when clinical trials have been undertaken.Thus,accumulating data suggest that these agonists or antagonists might become as new pharmacotherapeutic candidates for the treatment of metabolic diseases.

关 键 词：G protein-coupled receptor ANTAGONIST AGONIST diabetes metabolic syndrome nonalcoholic steatohepatitis 

分 类 号：R96[医药卫生—药理学]